The Share

The Diamyd Medical share is traded on Nasdaq First North Growth Market (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North Growth Market

Nasdaq First North Growth Market is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North Growth Market are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North Growth Market may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North Growth Market

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399, E-mail: info@fnca.se.

Analysts

Analysts following Diamyd Medical:
Ludvig Svensson, Penser Access by Carnegie, Tel: +46 8 463 80 00. Penser Access by Carnegie

Annual Report

  November 29, 2023

Company Presentation

 February 23, 2024
  Quarterly Report 1 23/24, January 24, 2024
As we progress into 2024, I am pleased to report significant advancements in Diamyd Medical's journey towards making the first-ever precision medicine treatment available for patients with type 1 diabetes. The recent U.S. market research has yielded promising insights. It demonstrates a strong willingness among healthcare practitioners and payers to consider prescribing Diamyd® for type 1 diabetes to the approximately 40% of patients identified...
The recent U.S. market research has yielded promising insights, demonstrating a strong willingness among healthcare practitioners and payers to consider prescribing Diamyd® for type 1 diabetes.
Ulf Hannelius, President and CEO

Calendar

  
Data pager
Data pager
12
March 6 − March 9, 2024
ATTD 2024, Florence, Italy
March 6, 2024
Life Science-dagen 2024
Wallenberg Conference Centre, Gothenburg. Company presentation by CEO Ulf Hannelius at 11:15 CET.
March 18 − March 20, 2024
7th Antigen-Specific Immune Tolerance Summit
March 27, 2024
Quarterly Report II
Quarterly Report 2 2023/2024
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of December 29, 2023

ShareholderA SharesB SharesCapital %Votes %
Avanza Pension 12 212 121 12.86 10.21
Lindkvist, Bertil 8 613 339 9.07 7.20
Nordnet Pension 5 178 414 5.45 4.33
Essen-Möller, Anders * 741 630 3 017 040 3.96 8.72
Essen-Möller, Maria-Teresa 400 000 963 998 1.44 4.15
Konstruktions o Försäljningsaktiebolag 906 250 0.95 0.76
Essen-Möller, Jon 400 000 395 101 0.84 3.67
Esssen-Möller, Martin 400 000 310 953 0.75 3.60
Hillborg, Erika 400 000 248 434 0.68 3.55
Essenshaw, My 400 000 181 002 0.61 3.50
Remaining shareholders 60 179 714 63.38 50.31
Total 2 741 630 92 206 366 100.0 100.0

Order GAD for preclinical research

GAD PRODUCTS